Abstract
Metastasis is a complex multistep process influenced by tumor cell properties as well as by properties of the host. This is best exemplified with immunological tumor-host interactions. The aim of this presentation is to explore the possibilities of immunological interventions in metastasis. Various approaches have been tried in the past, such as the passive transfusion of monoclonal antibodies or of different types of cells of the immune system, such as NK cells, T cells, LAK cells (lymphokine activated killer cells) or TIL cells (tumor infiltrating lymphocytes). Other approaches aim at nonspecific activation of host defense mechanisms by biological response modifiers (biological or chemical reagents).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Altevogt P, Leidig S, Heckl-Östreicher B (1984) Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells. Cancer Res 44:5305–5313
Altevogt P, von Hoegen P, Leidig S, Schirrmacher V (1985) Effects of mutagens on the immunogenicity of tumor cells: immunological and biochemical evidence for altered cell surface antigens. Cancer Res 45:4270–4277
Altevogt P, von Hoegen P, Schirrmacher V (1986a) The effects of mutagens on the immunogenicity and antigenicity of murine high and low metastatic lymphomas. Proceedings of the 14th international cancer congress, Budapest, pp 21/27
Altevogt P, von Hoegen P, Schirrmacher V (1986 b) Immunoresistant metastatic tumor variants can reexpress their tumor antigen by treatment with agents that inhibit DNA-methylation. Int J Cancer
Austin FC, Boone CW (1979) Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 30:301–345
Bosslet K, Schirrmacher V (1981) Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med 154:557–561
Bosslet K, Schirrmacher V (1982) High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int J Cancer 29:195–202
Bosslet K, Schirrmacher V, Shantz G (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. Similar specificity patterns of protective anti-tumor immunity in vivo. Int J Cancer 24:303–313
Cassel WA, Garret RE (1965) Newcastle Disease Virus as an anti-neoplastic agent. Cancer 18:863
Kerbel RS, Man MS, Dexter D (1984) A model of human cancer metastasis: extensive spontaneous and artificial metastasis of a human pigmented melanoma and derived variant sublines in nude mice. J Natl Cancer Inst 72:93–108
Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30:279–299
Kramer MD, Robinson P, Vlodavsky I, Barz D, Friberger P, Fuks Z, Schirrmacher V (1985) Characterization of an extracellular matrix-degrading protease derived from a highly metastatic tumor cell line. Eur J Cancer Clin Oncol 21:307–316
Larizza L, Schirrmacher V, Pflüger E (1984a) Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone-marrow derived macrophage. J Exp Med 160:1579–1584
Larizza L, Schirrmacher V, Graf L, Pflüger E, Peres-Martinez M, Stöhr M (1984 b) Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer 34:699–707
North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1–42
Schirrmacher V (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B 10.D2 mice. Int J Cancer 24:80–86
Schirrmacher V (1980) Commentary. Shifts in tumor cell phenotypes induced by signals from the microenvironment: relevance for the immunobiology of cancer metastasis. Immunobiology 157:89–98
Schirrmacher V (1985) Cancer metastasis: experimental approaches, theoretical concepts and impacts for treatment strategies. Adv Cancer Res 43:1–73
Schirrmacher V, Shantz G, Clauer K, Komitowski D, Zimmermann H-P, Lohmann-Matthes ML (1979a) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation in vivo. Int J Cancer 23:233–244
Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hübsch D (1979b) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between the parental tumor line and its metastasizing variant. Int J Cancer 23:245–252
Schirrmacher V, Bosslet K, Altevogt P, Rußmann E, Beck L, Fogel M (1982a) Microenvironmental influences on tumor-host interactions studies with high and low metastatic tumor lines. Tumor progression and markers. Proceedings IV. meeting of EACR, Budapest 1981, Kugler, Amsterdam, pp 155–164
Schirrmacher V, Fogel M, Russmann E, Bosslet K, Altevogt P, Beck L (1982b) Antigenic variation in cancer metastasis. Immune escape versus immune control. Cancer Metastasis Rev 1:241–274
Schirrmacher V, von Hoegen P, Heicappell R, Altevogt P (1986a) Modulations of tumor cell immunogenicity leading to increased T cell reactivity and decreased metastasis formation. In: Herberman RB, Wiltrout R, Gorelik E (eds) Immune responses to metastases. CRC Press, Boca Raton
Schirrmacher V, Braun M, Waller CA, Benke R, Larizza L (1986b) Changes in adhesive, invasive and metastatic capacity of a T lymphoma after fusion with a bone marrow derived macrophage. In: Macher E, Sorg C (eds) Local immunity in cancer. Reyen and Biermann, pp 72–83
Schirrmacher V, Ahlert T, Heicappell R, Appelhans B, von Hoegen P (1986c) Successful application of non-oncogenic viruses for anti-metastatic cancer immunotherapy. Cancer Rev
Storch E, Kirchner H, Schirrmacher V (1986) Prolonged survival of mice against the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum. Cancer Immunol Immunother
Vlodavsky I, Schirrmacher V, Ariav Y, Fuks Z (1983a) Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance. Invasion Metastasis 3:81–97
Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983b) Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 43:2704–2711
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schirrmacher, V. (1989). Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy. In: Drahovsky, D., Kornhuber, B. (eds) Human Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73642-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-73642-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19219-0
Online ISBN: 978-3-642-73642-1
eBook Packages: Springer Book Archive